Biotech Values

[DewDiligence]

ALIM/PSDV—Perhaps FDA said, “we will not RTF if you resubmit without a new study.”

You must be even more cynical than I am to posit such a scenario (assuming you were serious).

Given the content of the PR’s ALIM and PSDV issued Wednesday evening, these companies will be in legal hot water if FDA does not approve Iluvien on the current review cycle.